X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 15, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15

Reporting Person: GRAY MICHAEL (Director, See Remarks)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$9.39	2026-07-19	Common Stock (51274)		Direct
Stock Option (right to buy)	$4.00	2027-06-18	Common Stock (97665)		Direct

Footnotes

F1: This option was granted on July 20, 2016 and vests over four years, with 25% of the original 51,274 shares underlying the option having vested on July 20, 2017, and 2.0833% of the original 97,665 shares vesting monthly thereafter, subject to continued service.

F2: This option was granted on June 19, 2017 and vests over four years, with 25% of the original 97,665 shares underlying the option vesting on June 19, 2018, and 2.0833% of the original 97,665 shares vesting monthly thereafter, subject to continued service.